Lil­ly, In­cyte's baric­i­tinib wins fast-track sta­tus for hard-to-treat lu­pus; Syn­thorx ham­mers out $150M+ IPO

→ Rheuma­toid arthri­tis drug Olu­mi­ant — ap­proved for a nar­row­er-than-ex­pect­ed pa­tient pop­u­la­tion ear­li­er this year to the dis­may of its man­u­fac­tur­er Eli Lil­ly $LLY and In­cyte $IN­CY which had block­buster dreams for the drug — may be worth its weight in gold if ap­proved for lu­pus, a dis­ease in which the im­mune sys­tem at­tacks its host, and has seen a soli­tary ap­proved treat­ment in the last 50 years. The com­pa­nies an­nounced on Thurs­day that the drug, known chem­i­cal­ly as baric­i­tinib, had been grant­ed fast-track sta­tus by the FDA for lu­pus. Two dos­es of baric­i­tinib, which is al­so be­ing in­ves­ti­gat­ed as a treat­ment for atopic der­mati­tis, are cur­rent­ly in Phase III tri­als in pa­tients with sys­temic lu­pus ery­the­mato­sus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.